AstraZeneca partners with Oracle for AI-driven clinical trials
· CNA · JoinRead a summary of this article on FAST.
Get bite-sized news via a new
cards interface. Give it a try.
Click here to return to FAST Tap here to return to FAST
FAST
Oct 20 : AstraZeneca said on Tuesday that it is working with Oracle to use AI and real-world data to identify eligible patients for clinical trials and monitor safety signals, among other measures, as the drugmaker looks to improve clinical research.
• The collaboration will combine AstraZeneca's drug development expertise with Oracle's AI and healthcare data capabilities to support patient matching and research
• Initial work will focus on cancer, cardiovascular, respiratory, immunology and rare diseases, and could also support earlier diagnosis of serious diseases
• The first project will support hypertension research in Abu Dhabi in partnership with UAE-based healthcare firm M42
CNA Games
Guess Word
Crack the word, one row at a time
Buzzword
Create words using the given letters
Mini Sudoku
Tiny puzzle, mighty brain teaser
Mini Crossword
Small grid, big challenge
Word Search
Spot as many words as you can
Show More
Show Less
• Patient recruitment remains one of the biggest challenges in clinical research, with delayed enrolment often extending trial timelines and increasing development costs
• Incorrect trial designs have also hurt AstraZeneca in the past, with delays on its breast cancer drug and nerve disorder treatment failure causing some worries
• AstraZeneca is seeking to expand its medicine portfolio as it targets over $80 billion in annual revenue by 2030, and works to address industry bottlenecks in drug development
Newsletter
Week in Review
Subscribe to our Chief Editor’s Week in Review
Our chief editor shares analysis and picks of the week's biggest news every Saturday.
Sign up for our newsletters
Get our pick of top stories and thought-provoking articles in your inbox
Get the CNA app
Stay updated with notifications for breaking news and our best stories
Get WhatsApp alerts
Join our channel for the top reads for the day on your preferred chat app